Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.

[1]  M. Linton,et al.  Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation , 2013, Circulation.

[2]  F. Raal,et al.  Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy , 2013, Journal of the American Heart Association.

[3]  J. Kastelein,et al.  The PCSK9 decade , 2012, Journal of Lipid Research.

[4]  F. Raal,et al.  Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole , 2012, Circulation.

[5]  A. Shaywitz,et al.  Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. , 2012, Journal of the American College of Cardiology.

[6]  Jonathan C. Cohen,et al.  Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR , 2012, Journal of Lipid Research.

[7]  T. Michael.  Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia , 2012 .

[8]  K. Berge,et al.  Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. , 2012, Translational research : the journal of laboratory and clinical medicine.

[9]  Robert Dufour,et al.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial , 2012, The Lancet.

[10]  N. Seidah,et al.  Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters , 2010, Journal of Lipid Research.

[11]  S. Humphries,et al.  Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. , 2009, Clinical chemistry.

[12]  Annik Prat,et al.  Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte‐specific low‐density lipoprotein receptor degradation and critical role in mouse liver regeneration , 2008, Hepatology.

[13]  A. Keech,et al.  Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. , 2008, Clinical chemistry.

[14]  R. Cummings,et al.  Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of one figure. Published, JLR Papers in Press, March 19, 2008. , 2008, Journal of Lipid Research.

[15]  A. Marais,et al.  Familial hypercholesterolaemia: the Cape Town experience. , 2008, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[16]  Dojun Yoon,et al.  Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2s⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data. Published, JLR Papers in Press, November 21, 2007. , 2008, Journal of Lipid Research.

[17]  P. Barter,et al.  Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. , 2008, Atherosclerosis.

[18]  R. Hegele,et al.  Missense Mutations in APOB within the βα1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia* , 2007, Journal of Biological Chemistry.

[19]  Y. Qian,et al.  Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007. , 2007, Journal of Lipid Research.

[20]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[21]  R. Hammer,et al.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. , 2006, The Journal of clinical investigation.

[22]  I. Braakman,et al.  Low-density lipoprotein receptor structure and folding , 2004, Cellular and Molecular Life Sciences CMLS.

[23]  L. Bernier,et al.  Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[24]  B. Miskie,et al.  A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia* , 2003, The Journal of Biological Chemistry.

[25]  D. Blom,et al.  Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia Published, JLR Papers in Press, September 1, 2002. DOI 10.1194/jlr.D200013-JLR200 , 2003, Journal of Lipid Research.

[26]  A. Marais,et al.  Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry , 1999, Clinical genetics.

[27]  G. Coetzee,et al.  FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[28]  G. Coetzee,et al.  Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  W. D. de Villiers,et al.  Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. , 1993, Atherosclerosis.

[30]  R Bailén Almorox,et al.  [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol]. , 2012, Revista clinica espanola.